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Objective: Production of b-lactamase by pathogens causing urinary tract infection (UTI) has been dem-
onstrated to increase resistance to antimicrobial agents. The current study showed the prevalence of
uropathogens and their antimicrobial susceptibilities, based on extended-spectrum b-lactamase (ESBL)
production, in Dhaka.
Materials and Methods: The prevalence of uropathogens and their antimicrobial resistance patterns were
identiﬁed in 200 isolates from patients with UTI. Double-disc diffusion and E tests were performed to
determine the presence of ESBL-producing strains.
Results: The most common pathogen was Escherichia coli (57%), followed by Enterococcus spp. (10.5%),
Klebsiella spp. (11%), Staphylococcus spp. (4%), Pseudomonas spp. (10%), Acinetobacter spp. (5%), and
Enterobacter spp. (9%). ESBL production occurred more frequently in Klebsiella spp. (72.7%) than E. coli
(53.5%), and Enterobacter spp. (66.7%).
Conclusion: The current investigation found E. coli to be the most common uropathogen. Overall, the
higher frequency of antimicrobial resistance as well ESBL production by the most common pathogens
found in this study may demonstrate a public health threat and therefore, the community should be
made aware of this problem.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Urinary tract infection (UTI) is known to affect approximately
150 million people each year. It is the second most common
infection, and is responsible for approximately sevenmillion doctor
visits per year [1,2]. The frequency of infection varies especially
with age and sex [3,4]. Among uropathogens, Escherichia coli is
responsible for 80% of community-acquired UTI and 40% of
healthcare-associated UTI. Other uropathogens include Candida
spp., Proteus mirabilis, Staphylococcus and Klebsiella spp. [4e6].
Interestingly, uropathogens can change their physiologic features
to induce antimicrobial resistance [7].
The increase in antibiotic resistance among uropathogens is
a global problem [8].
The production of extended-spectrum b-lactamase (EBSL) en-
zymes, which are capable of hydrolyzing oxyimino b-lactamogy, Stamford University, 51,
2 8355596x472; fax: þ880 2
.
ddhist Compassion Relief Tzu Chicompounds, is one of the factors contributing to high resistance
against b-lactam antibiotics [9]. ESBLs demonstrate substrate spe-
ciﬁcity for most penicillins and ﬁrst-, second-, and third-generation
cephalosporins and aztreonam (not including cephamycins and
carbepenems) [9,10]. ESBLs can hydrolyze these antibiotic agents
but they can also be inhibited by b- lactamase inhibitors (clavulanic
acid) [10]. The most common plasmid-mediated b- lactamases
responsible for resistance to ampicillin are TEM-1, which can be
found in Gram-negative bacilli such as E. coli, and Klebsiella pneu-
moniae-producing SHV-1 b- lactamase [10]. It is important to know
the prevalence of ESBL in uropathogens for appropriate empirical
treatment of UTI [9].
In developing countries, increased antibiotic resistance can be
attributed to antibiotic abuse [11]. The current study was designed
to show the distribution of uropathogens and the prevalence of
ESBLeproducing uropathogens.
2. Materials and methods
The study was carried out in the Department of Microbiology,
Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangla-
desh from July 2010 to June 2011. Two hundred clinical specimensFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 2
Age distribution of ESBL-producing organisms (%).
Age (y) Total UTI sample ESBL positive ESBL negative
0e10 20 50 50
11e20 18 44 56
21e30 44 30 70
31e40 30 26 74
41e50 37 51 49
51e60 25 56 44
61e70 11 55 45
Older than 70 15 27 73
S.A. Khan et al. / Tzu Chi Medical Journal 25 (2013) 39e4240(including urine, pus, sputum, and swabs) were collected from in-
patients (n¼ 121) and outpatients (n¼ 79) at the hospital.
2.1. Isolation and identiﬁcation of uropathogens
Uropathogens were identiﬁed through culture, microscopy,
and biochemical tests. HighChrome chromogenic agar media,
MacConkey agar, blood agar, chocolate agar, and Oxoid clarity agar
media (Oxoid Ltd., Hampshire, UK) were inoculated with 100 mL of
urine from samples, and incubated at 37 C for 24 hours. Bacterial
identiﬁcation was done by phenotypic examination of the culture,
looking for typical characteristics, and by Gram staining, and a se-
ries of standard biochemical tests were also performed to identify
the bacteria of interest [12,13].
2.2. Antibiotic susceptibility testing
The agar disc diffusion assay was used to determine the anti-
microbial susceptibilities of uropathogens. The discs used in this
study included amikacin 20 mg, imipenem 10 mg, netilmicin sulfate
20 mg, ciproﬂoxacin 5 mg, nitrofurantoin 30 mg, cloxacillin 5 mg,
amoxicillin 10 mg, cephradine 20 mg, cotrimoxazole 25 mg, nalidixic
acid 30 mg, mecillinam 30 mg, ceftriaxone 30 mg, cefotaxime 30 mg,
gentamicin 30 mg, ceftazidime 30 mg, cefuroxime 30 mg, and
aztreonam 10 mg. The protocol for antibiotic susceptibility testing
has been described previously [14,15]. The diameters of the zones of
inhibition for individual antimicrobial agents were translated into
susceptible, intermediate, and resistant categories according to
National Committee for Clinical Laboratory Standards criteria [16].
2.3. Detection of ESBL by the double disc diffusion method
Positive (K. pneumoniae ATCC700603) and negative (E. coli ATCC
25922) control strains were inoculated onto Muller-Hinton agar
(HiMedia Laboratories Pvt. Ltd., Mumbai, India). An amoxicillin
clavulanic acid (20 mg þ 10 mg) disc was placed on the center of the
plate. Ceftazidime (30 mg), ceftriaxone (30 mg), cefotaxime (30 mg),
and aztreonam (30 mg) discs were placed peripherally away from
the amoxicillin clavulanic acid disc [17]. After 24hours of incubation
at 37 C, band formation between the amoxicillin clavulanic acid
disc and any other disc was considered ESBL positive [17]. The ESBL
positive strains were further subjected to phenotypic conﬁrmatory
tests using sensitivity discs, which contained third-generation
cephalosporins both with and without clavulanic acid. The discs
used included cefotaxime (30 mg), cefotaxime þ clavulanic acid
(30 mg þ 10 mg), ceftazidime (30 mg), ceftazidime (30 mg þ 10 mg),
aztreonam (10 mg), and aztreonamþ clavulanic acid (30 mgþ 10 mg).
The differences in the zone of inhibition caused by the cephalo-
sporins alone and when combined with clavulanic acid were
recorded and if the difference was 5 mm or more, the strains were
conﬁrmed as ESBL-producing strains [17].Table 1
Patterns of pathogenic isolates from UTI sample.
Pathogenic bacteria Total no. of organisms Male
Escherichia coli 114 (57%) 56 (49%)
Enterococcus spp. 21 (10.5%) 5 (24%)
Pseudomonas spp. 20 (10%) 12 (60%)
Enterobacter spp. 18 (9%) 13 (72%)
Klebsiella spp. 11 (5.5%) 6 (55%)
Acinetobacter spp. 10 (5%) 6 (60%)
Staphylococcus spp. 4 (2%) 2 (50%)
Citrobacter spp. 1 (0.5%) 1 (100%)
Proteus spp. 1 (0.5%) 1 (100%)
The experiments were in triplicates and the results were reproducible.The ESBL screening E test strip (AB Biodisk, Solna, Sweden) is
designed to detect the reduction in the ceftazidime minimum
inhibitory concentration (MIC) in the presence of clavulanic acid
with a ﬁxed concentration of 2 mg/mL. A gradient of ceftazidime
was created on one end and a gradient of combined ceftazidime
and clavulanic acid was created on the other end. ESBL-producing
strains were conﬁrmed if the MIC in the presence of clavulanic
acid was reduced by more then four dilution steps in comparison
with ceftazidime alone [18].
3. Results
Among 200 samples, E. coli was the predominant pathogenic
isolate (114 of 200), followed by Enterococcus spp., Pseudomonas
spp., Enterobacter spp., Klebsiella spp., Acinetobacter spp., Staphylo-
coccus spp, Citrobacter spp., and Proteus spp. (Table 1). E. coli was
more likely to cause UTIs in females whereas Pseudomonas spp.,
Acinetobacter spp., and Enterobacter spp. were more likely in males.
The prevalence of UTIs caused by Klebsiella and Staphylococcuswere
similar in males and females. Both Citrobacter and Proteus were
seen only in onemale patient each. This study foundmost UTI cases
occurred in those 21e30 years old (44%), followed by those 41e50
years old (37%). However, UTI patients 41e50 years old (19%) were
more likely to have ESBL-producing uropathogens. Those between
the ages of 21e30 (31%) and 31e40 (22%) years were more likely to
have ESBL negative strains.
3.1. Prevalence of ESBL-producing organisms
Identiﬁed isolates were further tested for the production of ESBL
(Table 1). Sixty-one of the total 114 E. coli identiﬁed were positive
for ESBL. Twenty of the 21 Enterococcus isolates were negative for
ESBL; 18 of 20 Pseudomonas spp. samples were negative and 12 of
the 18 samples of Enterobacter spp. were positive. Eight of the 11
Klebsiella spp. samples were ESBL positive and eight of 10 samples
of Acinetobacter spp. were negative. All four Staphylococcus spp.,
one Citrobacter spp., and one Proteus spp. samples were found to be
ESBL negative. The prevalence of ESBL was higher in those 41e60
years old and was lowest in those older than 70 years (Table 2).Female ESBL positive ESBL negative
58 (51%) 61 (53.5%) 53 (46.5%)
16 (76%) 1 (4.8%) 20 (95.2 %)
8 (40%) 2 (20%) 18 (80%)
5 (28%) 12 (66.7%) 6 (33.3%)
5 (45%) 8 (72.7%) 3 (27.3)
4 (40%) 2 (20%) 8 (80%)
2 (50%) 0 (0%) 4 (100%)
0 0 (0%) 1 (100%)
0 0 (0%) 1 (100%)
Table 4
Antibiotic susceptibility pattern of nonfermentative isolates (%).
Organisms
Antibiotics
Pseudomonas spp. Acinetobacter spp.
R S R S
AMO (10 mg) ND ND 100 0
CLO (5 mg) ND ND ND ND
CEPH (20 mg) ND ND 100 0
CTX (25 mg) ND ND 100 0
CIP (5 mg) 65 35 90 10
NIT (30 mg) ND ND ND ND
NLA (30 mg) ND ND ND ND
MCL (30 mg) 10 90 ND ND
CEF (30 mg) 81 19 90 10
GEN (30 mg) 72.7 27.3 90 10
CPX (30 mg) 80 20 80 20
CFZ (30 mg) 80 20 80 20
CFX (30 mg) 100 0 87.5 12.5
AMI (20 mg) 50 50 33.3 66.7
AZT (10 mg) 95 5 100 0
IMI (10 mg) 33.3 66.7 10 90
NTS (20 mg) 60 40 33.3 66.7
Theexperimentswere in triplicate and the resultswere reproducible. AMI¼ amikacin;
AMO¼ amoxicillin; AZT¼ aztreonam; CEF¼ ceftriaxone; CEPH¼ cephradine;
CFX¼ cefuroxime; CFZ¼ ceftazidime; CIP¼ ciproﬂoxacin; CLO¼ cloxacillin;
CPX¼ cefotaxime; CTX¼ cotrimoxazole; GEN¼ gentamicin; IMI¼ imipenem;
MCL¼mecillinam; ND¼ not deﬁned; NIT¼ nitrofurantoin; NLA¼ nalidixic acid;
NTS¼ netilmicin sulfate; R¼ resistant; S¼ sensitive.
S.A. Khan et al. / Tzu Chi Medical Journal 25 (2013) 39e42 41In this study, ESBL positive isolates were mainly identiﬁed in
E. coli (53.5%), Klebsiella spp. (72.7%), and other members of the
Enterobacteriaceae family such as Acinetobacter spp. and Enter-
obacter spp.
3.2. Antibiogram proﬁle of the uropathogens
Among all the isolates tested, E. coli and Staphylococcus spp.
showed the lowest levels of resistance against most of the antibiotic
agents. E. coli showed 1.1% resistance against imipenem, 2% resist-
ance against nitrofurantoin, 7.1% resistance against amikacin, and
7.7% resistance against amoxicillin (Table 3). Of four samples of
Staphylococcus spp. tested, no resistance was observed against
cloxacillin, cefotaxime, cefuroxine, amikacin, and imipenem. E. coli
and Staphylococcus spp. showed the highest levels of resistance
against amoxicillin (92.3% and 100%, respectively). Enterobacter spp.
showed 100% sensitivity only to imipenem. It also showed high
levels of sensitivity to amikacin and netilmicin sulfate (92.9% and
91.7%, respectively). Enterobacter spp. showed 100% resistance
against amoxicillin, ceftazidime, and aztreonam. Klebsiella spp.
showed the lowest level of resistance against imipenem and the
highest level of resistance against amoxicillin, aztreonam, cefotax-
ime, ceftazidime, and cefuroxine. Only one sample of Enterococcus
spp. was tested for susceptibility to cloxacillin and was found to be
resistant. However, the pathogenwas highly sensitive to imipenem
(88.2 %) and nitrofurantoin (80%), whereas it was 100% resistant
against nalidixic acid, ceftazidime, cefuroxine, and aztreonam.
High levels of resistance against most of the antibiotic agents
was observed in cases of nonfermentative isolates (Table 4). Pseu-
domonas spp. showed 100% resistance against mecillinam and
cefuroxine. Resistance against all other drugs was above 50%. Aci-
netobacter showed the highest levels of resistance against amox-
icillin, cephradine, cotrimoxazole, and aztreonam. Acinetobacter
spp. and Pseudomonas spp. showed low levels of resistance to
imipenem (10% and 33.3%, respectively).
4. Discussion
The current study was conducted to identify various microor-
ganisms that may be involved in the development of UTI and
determine their antibiotic resistance patterns as well as their ESBLTable 3
Antibiotic susceptibility pattern of the pathogenic isolates (%).
Pathogens Gram negative
E. coli (n¼ 114) Enterobacter spp. (n¼ 18) Klebsiella sp
Antibiotics R S R S R
AMO (10 mg) 7.7 92.3 100 0 100
CLO (5 mg) ND ND ND ND ND
CEPH (20 mg) 55.6 44.4 80 20 62.5
CTX (25 mg) 48.6 51.4 36.4 63.6 33.3
CIP (5 mg) 65.2 34.8 50 50 60
NIT (30 mg) 2 98 12.5 87.5 50
NLA (30 mg) 85.9 14.1 60 40 60
MCL (30 mg) 24.7 75.3 44.4 55.6 50
CEF (30 mg) 41.9 58.1 55.6 44.4 80
GEN (30 mg) 25.9 74.2 41.7 58.3 66.7
CPX (30 mg) ND ND 85.7 14.3 100
CFZ (30 mg) ND ND 100 0 100
CFX (30 mg) ND ND 83.3 16.7 100
AMI (20 mg) 7.1 92.9 7.1 92.9 14.3
AZT (10 mg) ND ND 100 0 100
IMI (10 mg) 1.1 98.9 0 100 10
NTS (20 mg) ND ND 7.7 92.3 20
The experiments were in triplicate and the results were reproducible. AMI¼ amika
CFX¼ cefuroxime; CFZ¼ ceftazidime; CIP¼ ciproﬂoxacin; CLO¼ cloxacillin; CPX¼ cefota
ND¼ not deﬁned; NIT¼ nitrofurantoin; NLA¼ nalidixic acid; NTS¼ netilmicin sulfate; Ractivity. The prevalence of uropathogens found in this study was in
agreement with similar studies conducted in India and Sudan
[1,19]. Those studies and another study in Pakistan indicated that
the most common cause of UTI in Asian countries is E. coli [20].
Previous studies and the current study identiﬁed Pseudomonas spp.,
Klebsiella spp. and Enterobacter spp. as other common causes of UTI
[21,22]. Studies in Jordan found Enterobacteriaceae was the most
common cause of UTI [23]. Previous studies conducted in Dhaka
were also in agreement with the current results, conﬁrming E. coli
as the most common uropathogen in Bangladesh [24,25]. Studies in
Nigeria also claimed that E. coli and Pseudomonas spp. are the most
common uropathogens [26].
ESBL-producing organisms are known to exhibit important
therapeutic implications as they show resistance against third-
generation cephalosporins, broad-spectrum ampicillin, and mono-
bactams. In our study, E. coli showed higher resistance againstGram positive
p. (n¼ 11) Enterococcus spp. (n¼ 21) Staphylococcus spp. (n¼ 4)
S R S R S
0 31.6 68.4 100 0
ND 0 100 0 100
37.5 31.6 68.4 50 50
66.7 75 25 33.3 66.7
40 65 35 66.7 33.3
50 20 80 ND ND
40 100 0 ND ND
50 95 5 ND ND
20 85 15 25 75
33.3 57.1 42.9 25 75
0 42.9 57.1 0 100
0 100 0 ND ND
0 100 0 0 100
85.7 68 32 0 100
0 100 0 ND ND
90 11.8 88.2 0 100
80 46.3 53.7 100 0
cin; AMO¼ amoxicillin; AZT¼ aztreonam; CEF¼ ceftriaxone; CEPH¼ cephradine;
xime; CTX¼ cotrimoxazole; GEN¼ gentamicin; IMI¼ imipenem; MCL¼mecillinam;
¼ resistant; S¼ sensitive.
S.A. Khan et al. / Tzu Chi Medical Journal 25 (2013) 39e4242ciproﬂoxacin, nirtofurantoin, nalidixic acid, mecillinam, and genta-
micin than isolates previously tested in Europe [21], thus revealing
a trend of increasing antibiotic resistance of UTI-causing pathogens
in our country, as found previously [27]. Compared with previous
studies, the current investigation found higher resistance rates for
Gram-negative pathogens against nalidixic acid, cefuroxine, cefta-
zidime, and amoxicillin [22]. This increasing drug resistance de-
mands coordinated monitoring of drug activity and usage.
Antibiotic resistance in nonfermentative isolates was deter-
mined to be due to the rare but progressively rising rates of
resistance [23]. Moreover, nonfermentative isolates are commonly
found in soil and water and are able to infect immunocompromised
individuals [23]. In this study, nonfermentative isolates were found
to be highly resistant against cefotaxime, ceftazidime, cefuroxine,
and aztreonam. An important point in our study was that in
a clinical setting, imipenem would be the drug of choice because it
showed high levels of sensitivity (92.6%). Consequently, drugs to be
avoided include cefotaxime, ceftazidime, and cefuroxine. This study
was in agreement with Health Protection Agency guidelines, which
suggest that nitrofurantoin is one of the ﬁrst-line drugs for UTI [28].
Similar studies in London have also identiﬁed nitrofurantoin as the
most effective treatment choice [29].
Bangladesh has a large amount of antibiotic abuse due to the
easy availability of antibiotic agents without physician pre-
scriptions. Notably, similar studies in developed countries includ-
ing the United States and European countries have revealed lower
levels of resistance against most commonly used antibiotic agents,
because cases of abuse of antibiotic agents are unusual there
[29,30]. Developing countries including Bangladesh, Pakistan, and
India have problems with abuse of antibiotic agents [31]. Studies of
antibiotic resistance patterns in India, Pakistan, and some African
countries have revealed resistance rates similar to those observed
in our investigation [20,31,32].
Because of abuse of antibiotic agents, antibiotic resistance starts
earlier in Bangladesh compared with developed countries [25]. This
clinical complication not only remains a challenge for UTI erad-
ication but also for public health, and threatens the lives of in-
dividuals. The high resistance rate of pathogens to commonly used
antibiotic agents as found from our study samples from UTI pa-
tients puts patients at high risk. Hence, routine screening for
antibiotic susceptibility is recommended.
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